Earlier in the week, I alerted you to the quickening pace of buyouts in the biotech industry. And of course, the triple-digit profit potential.

With Big Pharma companies like Pfizer Inc. (PFE) paying more than 200% to snap up compelling biotech companies, we’d be fools not to add several compelling takeover targets to our portfolios.

Stat!

Here’s the thing, though: I don’t want you to mistakenly believe that the only way to profit in biotech is from takeover announcements.

Not hardly!

Fact is, I’ve been pounding the table to buy biotech stocks for the better part of two years. And the results have been nothing short of amazing.

Let me prove it, and then I’ll share with you my Top Biotech Stock for right now.

I’m so bullish on this one that I have $300,000 of my own money in it.

And I believe it could double in price in the next few days alone.

Up, Up and Away

As we all know, the markets change every day, and new investment trends emerge.

One of those trends hit unexpectedly at the beginning of 2020…

That’s when Covid-19 became a real threat — and for a handful of biotech companies that could provide testing and treatment options, a real opportunity.

I spotted this trend early and identified seven small biotech companies that stood to benefit the most.

The rest is history…

All seven started soaring in price almost immediately:

• Within 30 days, readers were locking in gains of 105% in GenMark Diagnostics (GNMK), and 116% in Vaxart (VXRT).
• Within 60 days, readers were locking in gains of 243% in Novavax (NVAX).
• And within 120 days, readers were locking in gains of 226% in Inovio Pharmaceuticals (INO) and 640% in Altimmune (ALT).

And for investors that held onto all their shares of Novavax until my final sell alert… they took home a staggering profit of 949.8% in just 136 days.

That’s a ten-bagger in just a few months.

And mind you, this wasn’t some fluke related to Covid-19.

Over the last twenty years, small biotech stocks have helped me routinely deliver triple-digit profits in rapid succession — including biotechs that were unrelated to Covid.

And I don’t expect that trend to end anytime soon.

In fact, I’m so bullish on biotech stocks — and so bullish on one company in particular — I’ve made it my single largest investment.

I have over $300,000 of my own hard-earned money invested in it.

Why so much? Because the company is working on what I believe will prove to be a “Plug & Play” cure for cancer, and then a cure for all manner of autoimmune and infectious diseases, as well.

Given its platform technology, and the takeover premiums in the biotech industry right now, I’m projecting this company will soon be worth billions of dollars… starting as soon as this week.

I stand to personally make over a million dollars in pure profit on this investment. And I want to make sure you don’t miss out on the opportunity, too.

So hurry up and click on the link below to find out all the details.

Time is of the essence, as the company is set to report new data this weekend.

If you don’t get positioned beforehand, you could regret it.

My Top Biotech Stock to Own Right Now

Ahead of the tape,

Tags: biotech pharma